Overview

Clinical Study of Neflamapimod in Patients With Primary Progressive Aphasia

Status:
RECRUITING
Trial end date:
2026-10-01
Target enrollment:
Participant gender:
Summary
The goal of this exploratory study is to evaluate the effect of neflamapimod in participants with nonfluent variant primary progressive aphasia (nfvPPA). We aim to evaluate the safety, pharmacokinetics and clinical effects of neflamapimod of participants with nfvPPA.
Phase:
PHASE2
Details
Lead Sponsor:
EIP Pharma Inc
Collaborator:
CervoMed, Inc